Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view

INTRODUCTION: In several studies, the chimeric antigen receptor T‐cell therapy tisagenlecleucel demonstrated encouraging rates of remission and lasting survival benefits in pediatric patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL). We assessed the cost‐effectiveness of tis...

Descripción completa

Detalles Bibliográficos
Autores principales: Thielen, Frederick W., van Dongen‐Leunis, Annemieke, Arons, Alexander M. M., Ladestein, Judith R., Hoogerbrugge, Peter M., Uyl‐de Groot, Carin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497258/
https://www.ncbi.nlm.nih.gov/pubmed/32289184
http://dx.doi.org/10.1111/ejh.13427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497258/
https://www.ncbi.nlm.nih.gov/pubmed/32289184
http://dx.doi.org/10.1111/ejh.13427

Ejemplares similares